We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+2.46%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$316M
AUM Growth
-$13.7M
Cap. Flow
-$6.98M
Cap. Flow %
-2.21%
Top 10 Hldgs %
98.55%
Holding
12
New
–
Increased
6
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$2.49M
2
EMBC icon
Embecta
EMBC
+$237K
3
UTHR icon
United Therapeutics
UTHR
+$134K
4
CAH icon
Cardinal Health
CAH
+$36.8K
5
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$36.7K

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$8.85M
2
KOD icon
Kodiak Sciences
KOD
+$702K
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$231K
4
BIIB icon
Biogen
BIIB
+$89.3K
5
EXEL icon
Exelixis
EXEL
+$41.7K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$30B
$50.4M 15.96%
176,826
-300
-0.2% -$89.3K
UTHR icon
2
United Therapeutics
UTHR
$25.8B
$44.7M 14.18%
202,715
+605
+0.3% +$134K
REGN icon
3
Regeneron Pharmaceuticals
REGN
$78.5B
$42.5M 13.47%
59,188
-300
-0.5% -$231K
EXEL icon
4
Exelixis
EXEL
$13.3B
$40.8M 12.92%
2,133,703
-2,165
-0.1% -$41.7K
ALKS icon
5
Alkermes
ALKS
$8.22B
$34.5M 10.94%
1,103,451
-292,346
-21% -$8.85M
CAH icon
6
Cardinal Health
CAH
$53.9B
$33.5M 10.6%
353,714
+436
+0.1% +$36.8K
TARO
7
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$24.4M 7.73%
643,080
+1,170
+0.2% +$36.7K
EMBC icon
8
Embecta
EMBC
$216M
$23.1M 7.33%
1,070,810
+8,687
+0.8% +$237K
ENTA icon
9
Enanta Pharmaceuticals
ENTA
$366M
$14.7M 4.66%
687,613
+84,312
+14% +$2.49M
VNDA icon
10
Vanda Pharmaceuticals
VNDA
$307M
$2.39M 0.76%
362,951
+1,391
+0.4% +$8.92K
KOD icon
11
Kodiak Sciences
KOD
$2.6B
$2.38M 0.75%
344,634
-114,855
-25% -$702K
EGRX
12
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$2.21M 0.7%
113,437
-300
-0.3% -$7.12K

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q2 2023 Portfolio in Review

As of Q2 2023, Krensavage Asset Management held 12 positions worth $316M, down 4.1% from $329M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Trading was light in Q2 2023: portfolio turnover was 0%. Krensavage Asset Management opened no new positions and made no exits, leaving the 12-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Krensavage Asset Management added most to Enanta Pharmaceuticals in Q2 2023, an estimated $2.49M increase.
  • Krensavage Asset Management's biggest Q2 2023 reduction was Alkermes, cutting an estimated $8.85M.
  • Krensavage Asset Management's ten largest holdings make up 99% of its $316M portfolio in Q2 2023.
  • Krensavage Asset Management opened 0 new positions and closed 0 in Q2 2023.
  • Krensavage Asset Management's portfolio value fell 4.1% quarter-over-quarter to $316M.

Based on Krensavage Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.